Normal Quantitative EEG (qEEG) Dataset (NormalEEG)

August 8, 2022 updated by: Intermountain Health Care, Inc.

Normal Quantitative EEG (qEEG) Dataset for the Use in Comparison With Patients Suffering Carbon Monoxide (CO) Poisoning

In this study, the investigators will collect EEG data in normal, healthy volunteers without a history of prior brain injury. This data will be analyzed by computer (quantitative, or qEEG) and stored in a normative database so that, in the future, the investigators can better understand and characterize the brain damage that can result from carbon monoxide (CO) poisoning and other types of brain injury.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

This is a pilot, prospective, non-comparative, non-invasive, minimal risk research study to obtain qEEG data on normal, healthy individuals to include in a normal control database for use in comparison with patients with CO poisoning and other types of brain injury. The use of anti-depressant medication use is relatively common in the general adult population. There is varying opinion whether anti-depressant medication alters an otherwise normal clinical EEG. We have included healthy individuals taking anti-depressant medication to determine if those medications influence the EEG. The EEG data will be collected, analyzed, and stored for use in future research studies and for clinical care. Evaluating patients with qEEG methodology may assist in diagnosis and treatment.

Study Type

Observational

Enrollment (Anticipated)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Utah
      • Salt Lake City, Utah, United States, 84143
        • Recruiting
        • Intermountain Healthcare, LDS Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Normal, healthy volunteers (adult men and women, ages 18-55) will be selected from a carefully screened convenience sample.

Description

Inclusion Criteria:

  • Men and women, from 18 to 55 years old at the time of study enrollment. Women who are greater than 6 weeks post-partum, who are breastfeeding are allowed to participate if they are able to finish the electroencephalography (EEG) without interruption.
  • Able to speak and read English as their primary language.
  • Agrees to, and appears able to, participate in all outcome assessments.
  • Demonstrates the ability to offer informed consent and signs the study informed consent document.

Exclusion Criteria:

  • Vulnerable populations including, prisoners, pregnant women, and minors.
  • Women who are less than 6 weeks post-partum.
  • Unwilling or unable to participate in planned study visits.
  • Any past history of brain injury due to trauma, surgery, hypoxia, infection, inflammation, toxicity (e. g., carbon monoxide poisoning), or cerebrovascular etiology.
  • Individuals with a diagnosis of, or a persistent history of, or symptoms of a neurological disorder (e.g., tinnitus, vertigo, chronic fatigue, numbness, tingling, chronic migraine, fibromyalgia, multiple sclerosis).
  • Currently undergoing therapy for affective disorders, behavioral disorders, or psychological disorders.
  • Diagnosis of post-traumatic stress disorder or sub-clinical post-traumatic stress symptoms.
  • Diagnosis of diabetes mellitus, type 1 and type 2.
  • Current complaints of brain injury symptoms such as cognitive or affective problems.
  • Known neuroimaging abnormalities.
  • Participants taking daily prescription drugs or oral over the counter medications beyond vitamins that could impact a normal outcome determined by the Principal Investigator (e.g., beta blockers).
  • Participants who are ≥45 may be taking statins or angiotensin converting enzyme (ACE) inhibitors.
  • Participants between the ages of 18-55 may be taking antidepressants indicated for depression or post-partum depression.
  • Oral or injectable contraceptives are permitted
  • Known atrial septal defect, including but not limited to patent foramen ovale.
  • History of bypass surgery.
  • History of hydrocephalus/microcephaly/macrocephaly.
  • History of developmental delay or learning disorder as a child.
  • Previous or current use of any illicit drug, at any age.
  • Current positive urine drug test for any illicit substance.
  • History, by self-report in the last year, of alcohol abuse.
  • Current or previous tobacco use, with the exception of minimal use during adolescence.
  • Use of any assistive hearing device, or unable to verbally communicate due to hearing loss.
  • History, by self-report, of receiving chemotherapy drugs or therapeutic ionizing radiation to the head.
  • Foreign material in the head.
  • Active malignancy or prior malignancy (except basal cell carcinoma) within the last 5 years.
  • Unable to abstain from caffeine products for at least a 2 hour interval.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Ages 18-35, no antidepressant use
Ages 18-35, up to 15 males and 15 females, no antidepressant use
Electroencephalography (EEG) is a relatively inexpensive measurement of basic brain activity. Traditional EEG techniques rely on the clinician to visually examine the electrical current waveforms to identify abnormal signal patterns and slowing. Abnormalities on EEG have been reported following CO poisoning, though the literature is scarce. While current EEG technologies record EEG signals digitally, rather than writing directly to paper, computer-assisted analysis of the data (quantitative EEG, or qEEG) has not been widely embraced, in part because clinicians are unsure what patterns revealed by computer-assisted analysis represent abnormal activity.
Other Names:
  • EEG
Ages 36-55, no antidepressant use
Ages 36-55, up to 15 males and 15 females, no antidepressant use
Electroencephalography (EEG) is a relatively inexpensive measurement of basic brain activity. Traditional EEG techniques rely on the clinician to visually examine the electrical current waveforms to identify abnormal signal patterns and slowing. Abnormalities on EEG have been reported following CO poisoning, though the literature is scarce. While current EEG technologies record EEG signals digitally, rather than writing directly to paper, computer-assisted analysis of the data (quantitative EEG, or qEEG) has not been widely embraced, in part because clinicians are unsure what patterns revealed by computer-assisted analysis represent abnormal activity.
Other Names:
  • EEG
Ages 18-55, with antidepressant use
Ages 18-55, up to 10 males and 10 females, taking antidepressants
Electroencephalography (EEG) is a relatively inexpensive measurement of basic brain activity. Traditional EEG techniques rely on the clinician to visually examine the electrical current waveforms to identify abnormal signal patterns and slowing. Abnormalities on EEG have been reported following CO poisoning, though the literature is scarce. While current EEG technologies record EEG signals digitally, rather than writing directly to paper, computer-assisted analysis of the data (quantitative EEG, or qEEG) has not been widely embraced, in part because clinicians are unsure what patterns revealed by computer-assisted analysis represent abnormal activity.
Other Names:
  • EEG

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Electroencephalography Completion Questionnaire (Y/N)
Time Frame: Baseline
Electroencephalography study completed for the participant. (Y/N)
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2014

Primary Completion (Anticipated)

December 1, 2023

Study Completion (Anticipated)

December 1, 2023

Study Registration Dates

First Submitted

February 19, 2015

First Submitted That Met QC Criteria

February 27, 2015

First Posted (Estimate)

March 2, 2015

Study Record Updates

Last Update Posted (Actual)

August 10, 2022

Last Update Submitted That Met QC Criteria

August 8, 2022

Last Verified

August 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 1024985

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Carbon Monoxide Poisoning

Clinical Trials on Electroencephalography

3
Subscribe